How can we detect new targets to treat bowel cancer?
Cancer types:
Bowel cancer
Project period:
–
Research institute:
Istituto Superiore di Sanità (ISS)
Award amount:
£228,500
Location:
Italy
Dr Pichierri and his team want to find a new targeted treatment for bowel cancer. By shining a light on Werner Syndrome and discovering more about how it can lead to bowel cancer, the researchers hope to reveal new potential targets.
Hope for the future
Bowel cancer is the worlds’ third most common cancer despite recent improvements in screening and treatment. In 2022, an estimated 1.9 million people worldwide were diagnosed with bowel cancer. This innovative project funded by Curestarters hopes to find a new cure for this devastating disease.
Werner Syndrome is a rare genetic condition that increases the risk of bowel cancer, but not much is known about how it does so. Dr Pichierri is an expert on Werner Syndrome and he has been studying its links to cancer. He recently had the brilliant idea that by better understanding the genetic mutation that causes Werner Syndrome could uncover new therapeutic targets for bowel cancer.
Meet the scientist
Out of the lab, Pietro enjoys relaxing with his family. Of course, being Italian he is convinced that the best food is Italian and he loves pizza and spaghetti, especially with fish.
The science
In our DNA we have a gene called WRN, which makes proteins that are involved in important processes including repairing damaged DNA. Repairing DNA is a crucial process for our bodies to stay healthy, as damaged DNA is one of the causes of cancer.
It is this WRN gene that is affected in Werner syndrome - mutations in this gene lead to faulty WRN proteins being produced, which disrupts these important cellular processes. These particular mutations are also associated with genetic instability in bowel cancer, which makes WRN a promising target for cancer treatment.
Previous research has shown that the WRN protein works by interacting with several other proteins through different biological pathways, which Dr Pichierri and his team will now explore. In particular, WRN interacts with a protein called “Replication protein A” or RPA, which is vital for DNA repair and replication. The team aim to better understand the significance of how these proteins co-operate, and what that could mean for bowel cancer development.
The team in Italy will collaborate with partners in the UK and the USA to find potential therapeutic targets related to WRN. They hope that this international collaboration will lead to new treatments for bowel cancer that work through the targets they discover.
We would like to express our deep gratitude for your engagement in the support of Worldwide Cancer Research, and of research on cancer in general. Thank you, grazie mille di cuore!
Active Switzerland
Bowel cancer
Immunotherapy for cancer has huge potential but doesn’t always work, so this project hopes to find ways for it to cure more people with bowel cancer.
Researcher: Professor Alessandro Sartori
Developing bowel cancer immunotherapies that target DNA repair
Active Greece
Bowel cancer
This project hopes to reveal vital new ways to stop bowel cancer developing by better understanding how cancer cells and healthy cells interact.
Researcher: Dr Vasiliki Koliaraki
Understanding how colorectal tumours hijack healthy cells
Complete Spain
Bowel cancer
Sometimes cancer treatment stops working if cancers become resistant to therapy so this team hope to improve survival rates by exploring potential new drugs.
Researcher: Dr Maite Huarte
Identifying new therapeutic approaches for treatment-resistant bowel cancer